Mustang Bio R&D Spending Growth & History (MBIO)
Mustang Bio's r&d spending was −$1.5M for fiscal 2025.
View full Mustang Bio company overviewMustang Bio annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$1.5M | −$9.1M | — |
| 2024 | 2024-12-31 | $7.6M | −$33.0M | −81.35% |
| 2023 | 2023-12-31 | $40.5M | −$22.0M | −35.15% |
| 2022 | 2022-12-31 | $62.5M | $12.6M | +25.29% |
| 2021 | 2021-12-31 | $49.9M | $12.6M | +33.91% |
| 2020 | 2020-12-31 | $37.2M | $7.2M | +23.95% |
| 2019 | 2019-12-31 | $30.0M | $8.9M | +42.35% |
| 2018 | 2018-12-31 | $21.1M | $13.2M | +165.69% |
| 2017 | 2017-12-31 | $7.9M | $5.5M | +221.84% |
| 2016 | 2016-12-31 | $2.5M | — | — |
Mustang Bio quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $224,000 | $126,000 | +128.57% |
| Q1 2026 | 2026-03-31 | $178,000 | — | — |
| Q4 2025 | 2025-12-31 | −$317,000 | — | — |
| Q3 2025 | 2025-09-30 | −$333,000 | −$390,000 | — |
| Q2 2025 | 2025-06-30 | $98,000 | −$4.3M | −97.75% |
| Q3 2024 | 2024-09-30 | $57,000 | −$9.5M | −99.40% |
| Q2 2024 | 2024-06-30 | $4.4M | −$6.5M | −59.76% |
| Q1 2024 | 2024-03-31 | $3.8M | −$10.2M | −72.83% |
| Q4 2023 | 2023-12-31 | $6.2M | −$9.5M | −60.58% |
| Q3 2023 | 2023-09-30 | $9.5M | −$5.9M | −38.21% |
| Q2 2023 | 2023-06-30 | $10.8M | −$4.3M | −28.54% |
| Q1 2023 | 2023-03-31 | $14.0M | −$2.3M | −14.05% |
| Q4 2022 | 2022-12-31 | $15.6M | $2.3M | +17.66% |
| Q3 2022 | 2022-09-30 | $15.4M | $1.3M | +9.49% |
| Q2 2022 | 2022-06-30 | $15.2M | $4.3M | +39.09% |
| Q1 2022 | 2022-03-31 | $16.3M | $4.7M | +40.20% |
| Q4 2021 | 2021-12-31 | $13.3M | $3.2M | +31.22% |
| Q3 2021 | 2021-09-30 | $14.1M | $6.1M | +76.32% |
| Q2 2021 | 2021-06-30 | $10.9M | $1.1M | +10.91% |
| Q1 2021 | 2021-03-31 | $11.6M | $2.3M | +24.74% |
| Q4 2020 | 2020-12-31 | $10.1M | $1.2M | +12.92% |
| Q3 2020 | 2020-09-30 | $8.0M | $678,000 | +9.28% |
| Q2 2020 | 2020-06-30 | $9.8M | $3.0M | +44.07% |
| Q1 2020 | 2020-03-31 | $9.3M | $2.4M | +33.82% |
| Q4 2019 | 2019-12-31 | $8.9M | $1.0M | +12.73% |
| Q3 2019 | 2019-09-30 | $7.3M | $2.0M | +37.49% |
| Q2 2019 | 2019-06-30 | $6.8M | $3.3M | +91.82% |
| Q1 2019 | 2019-03-31 | $7.0M | $2.7M | +62.16% |
| Q4 2018 | 2018-12-31 | $7.9M | $5.4M | +210.72% |
| Q3 2018 | 2018-09-30 | $5.3M | $3.1M | +142.96% |
| Q2 2018 | 2018-06-30 | $3.6M | $1.1M | +42.62% |
| Q1 2018 | 2018-03-31 | $4.3M | $3.6M | +507.93% |
| Q4 2017 | 2017-12-31 | $2.6M | $1.8M | +240.67% |
| Q3 2017 | 2017-09-30 | $2.2M | $1.6M | +284.53% |
| Q2 2017 | 2017-06-30 | $2.5M | $1.9M | +328.52% |
| Q1 2017 | 2017-03-31 | $706,000 | $139,000 | +24.51% |
| Q4 2016 | 2016-12-31 | $750,000 | — | — |
| Q3 2016 | 2016-09-30 | $569,000 | −$1,000 | −0.18% |
| Q2 2016 | 2016-06-30 | $582,000 | — | — |
| Q1 2016 | 2016-03-31 | $567,000 | — | — |
| Q3 2015 | 2015-09-30 | $570,000 | — | — |
Mustang Bio r&d spending trends
Over the last five fiscal years, Mustang Bio's r&d spending decreased from $37.2M to −$1.5M, a change of −$38.8M. The latest reported quarter, Q2 2026, shows $224,000.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mustang Bio source filings ↗